The state of macular retinal volume at various degrees of pre-eclampsia
Session Details
Session Title: Presented Poster Session: Ocular Pathologies
Venue: Poster Village: Pod 3
First Author: : O.Kolenko RUSSIA
Co Author(s): : E. Sorokin
Abstract Details
Purpose:
Search for interdependencies between the biochemical factors of endothelial dysfunction and the macular retinal volume (MRV) in pregnant women with preeclampsia.
Setting:
The work was performed in the State Institution Eye Microsurgery Complex named after academician S.N. Fyodorov, Khabarovsk, Russia.
Methods:
Clinical material was presented by 42 pregnant women aged 21-40 years with signs of preeclampsia of varying degrees of severity (main group). The diagnosis of preeclampsia was confirmed by obstetrician-gynecologists on the basis of a complex of clinical and laboratory studies.
According to the severity of preeclampsia, three subgroups of the main group were formed: 1st subgroup - mild degree of preeclampsia – 22 women; 2nd subgroup – moderate preeclampsia – 12 women; 3rd subgroup – severe degree of preeclampsia – 8 women.
Control was 20 women of 19-38 years with a physiological pregnancy.
Results:
A progressive increase in the indices of the endothelin biochemical content in the lacrimal fluid was revealed as well as Von Willebrand factor in the blood serum, the MRV index at the increase in the severity of preeclampsia from mild to severe. A strong direct statistically significant relationship was found between the increase in endothelin level, Von Willebrand factor, on the one hand, and the MRV index, on the other hand, in the main group (correlation coefficients 0.75 and 0.71, respectively). Although in this case in most women visual acuity remained high.
Conclusions:
Probably, the presence of edema in the macular zone in women with preeclampsia of moderate and severe degrees in the 3rd trimester, even with its subsequent reduction, can create a risk of metabolic disorders of the macular zone in the near and distant postpartum periods, which can be expressed by the formation of macular pathology.
Financial Disclosure:
None